As of May 27
| +0.19 / +2.64%|
The 4 analysts offering 12-month price forecasts for ADMA Biologics Inc have a median target of 18.75, with a high estimate of 24.00 and a low estimate of 15.00. The median estimate represents a +154.07% increase from the last price of 7.38.
The current consensus among 4 polled investment analysts is to Buy stock in ADMA Biologics Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.